← Browse by Condition

Medical Condition

diffuse large b cell lymphoma

Total Trials

18

Recruiting Now

18

Trial Phases

Phase 2, Phase 3, Phase 1

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — diffuse large b cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for diffuse large b cell lymphoma?

ClinicalMetric currently tracks 18 actively recruiting clinical trials for diffuse large b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for diffuse large b cell lymphoma?

diffuse large b cell lymphoma research spans Phase 1 (7 trials), Phase 2 (5 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a diffuse large b cell lymphoma clinical trial?

Eligibility criteria for diffuse large b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

7

Phase 2

5

Phase 3

2

Top Sponsors

Ruijin Hospital 2 trials

Navy General Hospital, Beijing 1 trial

Institute of Oncology Ljubljana 1 trial

Novartis Pharmaceuticals 1 trial

C. Babis Andreadis 1 trial

Recruiting Clinical Trials

NCT06664411 Phase 2

Pola-ZR2P in Previously Untreated DLBCL

Navy General Hospital, Beijing

Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma

Institute of Oncology Ljubljan...

NCT04094311 Phase 3

Study of Out of Specification for Tisagenlecleucel

Novartis Pharmaceuticals

NCT06522555 Phase 3

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

Ruijin Hospital

NCT04545762 Phase 1

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

C. Babis Andreadis

NCT05256641 Phase 1, Phase 2

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Jonsson Comprehensive Cancer C...

NCT04512716 EARLY_Phase 1

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Memorial Sloan Kettering Cance...

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT06768905 Phase 1, Phase 2

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

University of Texas Southweste...

NCT06829771 Phase 1, Phase 2

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Chia Tai Tianqing Pharmaceutic...

NCT06395103 Phase 1, Phase 2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

United States, Austr...

Merck Sharp & Dohme LLC

Frontline of ASCT in High-risk DLBCL

Peking University People's Hos...

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Ruijin Hospital

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Medical College of Wisconsin

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Children's Hospital Medical Ce...

Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

The First Affiliated Hospital ...

NCT07528352 Phase 1

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

University of Utah

Related Conditions

burkitt lymphoma (4) follicular lymphoma (3) non hodgkin lymphoma (3) b cell acute lymphoblastic leukemia (2) mantle cell lymphoma (2) transformed lymphoma (2) b all (2) refractory non hodgkin lymphoma (1) lymphoplasmacytic lymphoma (1) primary mediastinal large b cell lymphoma (1) small lymphocytic lymphoma (1) high grade b cell lymphoma (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology